$SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Michael A. Metzger
CEO
270
Employees
$18.25
Current Price
$1.84B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $1,183,642.90 | 65,515 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 4 | $1,336,018.66 | 73,539 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 4 | $1,336,018.66 | 73,539 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 4 | $1,336,018.66 | 73,539 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 4 | $1,336,018.66 | 73,539 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | Botwood Nicholas A.J. Head of R&D, CMO | Sale | 31,235 | $18.14 | $566,602.90 | View Details |
| Jun 11, 2026 | Botwood Nicholas A.J. Head of R&D, CMO | Sale | 34,280 | $18.00 | $617,040.00 | View Details |
| Jun 1, 2026 | Goldan Keith A. Chief Financial Officer | Sale | 1,177 | $18.99 | $22,351.23 | View Details |
| Jun 1, 2026 | Metzger Michael A Director | Sale | 6,847 | $18.99 | $130,024.53 | View Details |
10 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.